Nonadjunctive Use of Continuous Glucose Monitoring for Diabetes Treatment Decisions

While self-monitoring of blood glucose (SMBG) is the current standard used by people with diabetes to manage glucose levels, recent improvements in accuracy of continuous glucose monitoring (CGM) technology are making it very likely that diabetes-related treatment decisions will soon be made based on CGM values alone. Nonadjunctive use of CGM will lead to a paradigm shift in how patients manage their glucose levels and will require substantial changes in how care providers educate their patients, monitor their progress, and provide feedback to help them manage their diabetes. The approval to use CGM nonadjunctively is also a critical step in the pathway toward FDA approval of an artificial pancreas system, which is further expected to transform diabetes care for people with type 1 diabetes. In this article, we discuss how nonadjunctive CGM is expected to soon replace routine SMBG and how this new usage scenario is expected to transform health outcomes and patient care.

[1]  Howard Wolpert,et al.  Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. The effect of continuous glucose monitoring in well-controlled type 1 diabetes , 2009 .

[2]  F. Ovalle,et al.  Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes , 2009 .

[3]  T. Bailey,et al.  Clinical Accuracy of a Continuous Glucose Monitoring System With an Advanced Algorithm , 2014, Journal of diabetes science and technology.

[4]  David M Nathan,et al.  Outpatient glycemic control with a bionic pancreas in type 1 diabetes. , 2014, The New England journal of medicine.

[5]  B. Ginsberg.  Factors Affecting Blood Glucose Monitoring: Sources of Errors in Measurement , 2009, Journal of diabetes science and technology.

[6]  David M. Maahs,et al.  Real-Time Continuous Glucose Monitoring Among Participants in the T1D Exchange Clinic Registry , 2014, Diabetes Care.

[7]  David C. Klonoff,et al.  Threshold-based insulin-pump interruption for reduction of hypoglycemia , 2014 .

[8]  T. Bailey,et al.  Continuous glucose monitoring health outcomes. , 2009, Diabetes technology & therapeutics.

[9]  Claudio Cobelli,et al.  Time Lag of Glucose From Intravascular to Interstitial Compartment in Type 1 Diabetes , 2014, Journal of diabetes science and technology.

[10]  J. Brauker,et al.  Analysis of time lags and other sources of error of the DexCom SEVEN continuous glucose monitor. , 2009, Diabetes technology & therapeutics.

[11]  Andreas Pfützner,et al.  Accuracy evaluation of five blood glucose monitoring systems obtained from the pharmacy: a European multicenter study with 453 subjects. , 2012, Diabetes technology & therapeutics.

[12]  W. Polonsky,et al.  Perceived Accuracy in Continuous Glucose Monitoring , 2014, Journal of diabetes science and technology.

[13]  Nicholas Preiser,et al.  Incorporating an Exercise Detection, Grading, and Hormone Dosing Algorithm Into the Artificial Pancreas Using Accelerometry and Heart Rate , 2015, Journal of diabetes science and technology.

[14]  B. Karon,et al.  Evaluation of the Impact of Hematocrit and Other Interference on the Accuracy of Hospital-Based Glucose Meters , 2008 .

[15]  J. Castle,et al.  The effect of rising vs. falling glucose level on amperometric glucose sensor lag and accuracy in Type 1 diabetes , 2012, Diabetic medicine : a journal of the British Diabetic Association.

[16]  Bruce Buckingham,et al.  Effect of Acetaminophen on CGM Glucose in an Outpatient Setting , 2015, Diabetes Care.

[17]  D. B. Keenan,et al.  Delays in Minimally Invasive Continuous Glucose Monitoring Devices: A Review of Current Technology , 2009, Journal of diabetes science and technology.

[18]  Ryuzo Kawamori,et al.  Glucose Monitoring After Fruit Peeling: Pseudohyperglycemia When Neglecting Hand Washing Before Fingertip Blood Sampling , 2011, Diabetes Care.

[19]  Marc D. Breton,et al.  Safety of Outpatient Closed-Loop Control: First Randomized Crossover Trials of a Wearable Artificial Pancreas , 2014, Diabetes Care.

[20]  BoettcherClaudia,et al.  Accuracy of blood glucose meters for self-monitoring affects glucose control and hypoglycemia rate in children and adolescents with type 1 diabetes. , 2015 .

[21]  B. Olsen,et al.  The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial , 2012, Diabetologia.

[22]  E. Atlas,et al.  Nocturnal glucose control with an artificial pancreas at a diabetes camp. , 2013, The New England journal of medicine.

[23]  A. D. Jeffrey,et al.  Evaluation of the Impact of Hematocrit and Other Interference on the Accuracy of Hospital-Based Glucose Meters , 2008 .

[24]  Roman Hovorka,et al.  Glucose control in the intensive care unit by use of continuous glucose monitoring: what level of measurement error is acceptable? , 2014, Clinical chemistry.

[25]  Buddy D Ratner,et al.  Biomechanics of the Sensor-Tissue Interface—Effects of Motion, Pressure, and Design on Sensor Performance and Foreign Body Response—Part II: Examples and Application , 2011, Journal of diabetes science and technology.

[26]  Ahmad Haidar,et al.  Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial. , 2015, The lancet. Diabetes & endocrinology.

[27]  M. Phillip,et al.  Effect of Continuous Glucose Monitoring on Hypoglycemia in Type 1 Diabetes , 2011, Diabetes Care.

[28]  Stephen D Patek,et al.  Assessing sensor accuracy for non-adjunct use of continuous glucose monitoring. , 2015, Diabetes technology & therapeutics.

[29]  W. Kenneth Ward,et al.  Automated Control of an Adaptive Bihormonal, Dual-Sensor Artificial Pancreas and Evaluation During Inpatient Studies , 2014, IEEE Transactions on Biomedical Engineering.

[30]  D. Price,et al.  HOW PATIENTS WITH TYPE 1 DIABETES TRANSLATE CONTINUOUS GLUCOSE MONITORING DATA INTO DIABETES MANAGEMENT DECISIONS. , 2015, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[31]  C. Cobelli,et al.  Time Lag of Glucose From Intravascular to Interstitial Compartment in Humans , 2013, Diabetes.

[32]  Aaron J. Kowalski.  Pathway to Artificial Pancreas Systems Revisited: Moving Downstream , 2015, Diabetes Care.

[33]  David M Maahs,et al.  Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry , 2015, Diabetes Care.

[34]  Roman Hovorka,et al.  Home Use of an Artificial Beta Cell in Type 1 Diabetes. , 2015, The New England journal of medicine.

[35]  George Dailey,et al.  Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. , 2010, The New England journal of medicine.

[36]  W Kenneth Ward,et al.  A review of the foreign-body response to subcutaneously-implanted devices: the role of macrophages and cytokines in biofouling and fibrosis. , 2008, Journal of diabetes science and technology.

[37]  W. Polonsky,et al.  What is so tough about self‐monitoring of blood glucose? Perceived obstacles among patients with Type 2 diabetes , 2014, Diabetic medicine : a journal of the British Diabetic Association.